Deutsche Bank AG Purchases 37,907 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Deutsche Bank AG lifted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 15.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 277,853 shares of the company's stock after acquiring an additional 37,907 shares during the period. Deutsche Bank AG owned about 0.19% of Denali Therapeutics worth $5,663,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sterling Capital Management LLC grew its stake in Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after purchasing an additional 885 shares during the period. KBC Group NV increased its holdings in shares of Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after purchasing an additional 2,731 shares during the period. AlphaQuest LLC increased its holdings in shares of Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock valued at $142,000 after purchasing an additional 4,449 shares during the period. Finally, E Fund Management Co. Ltd. increased its holdings in shares of Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Price Performance

Shares of DNLI stock traded down $0.24 during trading on Friday, reaching $13.42. The company had a trading volume of 786,274 shares, compared to its average volume of 1,100,099. The firm's 50 day simple moving average is $13.97 and its two-hundred day simple moving average is $19.12. Denali Therapeutics Inc. has a one year low of $10.57 and a one year high of $33.33. The company has a market capitalization of $1.95 billion, a PE ratio of -4.86 and a beta of 1.49.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.07). During the same quarter last year, the company earned ($0.68) earnings per share. Analysts forecast that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Analyst Ratings Changes

DNLI has been the topic of a number of research analyst reports. B. Riley reaffirmed a "buy" rating and set a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. Cantor Fitzgerald upgraded Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. Morgan Stanley started coverage on Denali Therapeutics in a research report on Friday, March 7th. They set an "overweight" rating and a $33.00 price objective for the company. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective for the company. Finally, Wedbush decreased their price objective on Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Denali Therapeutics has an average rating of "Buy" and an average price target of $33.71.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.